The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel

Neal Shore, MD, FACS, speculates on how the utilization of AR-pathway inhibitors and docetaxel in earlier lines of mCRPC treatment has also influenced treatment with cabazitaxel.

EP: 1.Case Presentation: A 74-Year-Old Man With Metastatic Prostate Cancer

EP: 2.Available Treatment Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy

EP: 3.Cabazitaxel for the Treatment of mCRPC: Data From the PROSELICA and FIRSTANA Trials

EP: 4.Cabazitaxel for the Treatment of mCRPC: Data From the CARD Trial

EP: 5.Factors for Consideration When Selecting Patients with mCRPC for Treatment With Cabazitaxel

EP: 6.Selecting Between Treatment With Cabazitaxel or Radiotherapy for Patients with mCRPC

Now Viewing

EP: 7.The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel

EP: 8.Unmet Needs and Clinical Pearls in mCRPC

Related Videos

Related Content

Advertisement

February 19th 2025

WOLVERINE findings highlight benefits of MDT in oligometastatic prostate cancer

Benjamin P. Saylor

Median PFS was 35 months in the MDT plus SOC group vs 21 months in the SOC alone group.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

February 14th 2025

Darolutamide plus ADT shows mHSPC benefit regardless of disease volume

Benjamin P. Saylor

"Efficacy outcomes with darolutamide plus ADT were improved vs placebo plus ADT regardless of disease volume," said Fred Saad, MD, FRCS.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

February 13th 2025

Darolutamide is safe, efficacious in mHSPC regardless of patient age

Benjamin P. Saylor

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.

February 13th 2025

Race subgroup analysis points to clinical benefit of darolutamide in nmCRPC

Benjamin P. Saylor

In both racial cohorts, median MFS was not reached in the darolutamide group.

Related Content

Advertisement

February 19th 2025

WOLVERINE findings highlight benefits of MDT in oligometastatic prostate cancer

Benjamin P. Saylor

Median PFS was 35 months in the MDT plus SOC group vs 21 months in the SOC alone group.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

February 14th 2025

Darolutamide plus ADT shows mHSPC benefit regardless of disease volume

Benjamin P. Saylor

"Efficacy outcomes with darolutamide plus ADT were improved vs placebo plus ADT regardless of disease volume," said Fred Saad, MD, FRCS.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

February 13th 2025

Darolutamide is safe, efficacious in mHSPC regardless of patient age

Benjamin P. Saylor

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.

February 13th 2025

Race subgroup analysis points to clinical benefit of darolutamide in nmCRPC

Benjamin P. Saylor

In both racial cohorts, median MFS was not reached in the darolutamide group.